Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
55 studies found for:    acute myelomonocytic leukemia | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
Interventions: Other: Antitumor Drug Screening Assay;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Other: Pharmacological Study;   Drug: Ponatinib Hydrochloride;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate
22 Recruiting Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia-2;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Drug: Idarubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pomalidomide
23 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention:
24 Recruiting Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Condition: Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: lenzilumab
25 Recruiting Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: azacitidine;   Biological: donor lymphocyte infusion
26 Recruiting Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Secondary Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Biological: Indium In 111 Anti-CD45 Monoclonal Antibody BC8;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
27 Not yet recruiting 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   CD45-Positive Neoplastic Cells Present;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Pretargeted Radioimmunotherapy;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
28 Recruiting Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Myeloproliferative Neoplasm;   Chronic Myelomonocytic Leukemia
Interventions: Drug: APR-246;   Drug: Azacitidine
29 Recruiting Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia
Condition: Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Tipifarnib
30 Recruiting A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
Condition: Leukemia, Myelomonocytic, Chronic
Interventions: Drug: Cohort 1, Ceplene® and Proleukin®;   Drug: Cohort 2, Ceplene® and Proleukin®;   Drug: Cohort 3, Ceplene® and Proleukin®
31 Recruiting Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Conditions: Leukemia;   Acute Myeloid Leukemia
Interventions: Drug: Selinexor;   Drug: Sorafenib
32 Recruiting Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Condition: Juvenile Myelomonocytic Leukemia
Interventions: Biological: Stem Cell Transplant;   Drug: Preparative Regimen
33 Recruiting Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies
Conditions: Myeloablative Conditioning;   HLA-mismatched Bone Marrow Transplantation;   Graft Survival;   Transplantion, Bone Marrow
Interventions: Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Busulfan;   Other: Unmanipulated Bone Marrow;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
34 Recruiting Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Conditions: Non-Hodgkin's Lymphoma;   Acute Leukemia in Remission;   Chronic Myeloid Leukemia;   Primary Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndromes;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Drug: Fludarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Radiation: Total body irradiation (TBI);   Procedure: Peripheral Blood Hematopoietic Cell Transplantation (HCT);   Drug: Sirolimus (SIR);   Drug: Mycophenolate mofetil (MMF);   Drug: Granulocyte-colony stimulating factor (G-CSF)
35 Recruiting Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Lymphoma,Non-Hodgkin;   Lymphoma, Hodgkin;   Lymphoma, Follicular;   Marginal Zone Lymphoma;   Large Cell Lymphoma;   Mantle-Cell Lymphoma;   Gray Zone Lymphoma;   Burkitt Lymphoma
Interventions: Drug: Bendamustine;   Drug: Cyclophosphamide
36 Recruiting Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Conditions: AML;   CMML;   MDS
Intervention: Drug: FF-10501-01
37 Not yet recruiting Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Conditions: Acute Leukemias;   Chronic Leukemias;   Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia
Intervention: Drug: Busulfan/Cyclophosphamide
38 Recruiting Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemia/Lymphoma;   Myelodysplasia;   Acute Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention:
39 Recruiting Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
Interventions: Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS
40 Recruiting Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Juvenile
Intervention: Drug: Azacitidine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-55) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.